

INFORMATION DISCLOSURE STATEMENT

(37 CFR 1.56, 1.97, and 1.98)

Attorney Docket Application No 25846-0003 09/693,558 Applicant(s) Elfi Bicdermann et al.

Sheet 1 of 1

Filing date Art Unit Ocrober 20, 2000 1614

OTHER DOCUMENTS				
† Ex'r initial	Doc. #	Citation (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)		
1/3	A7	Pozzilli et al., "Viramin E and nicotinamide have similar effects in maintaining residual bera cell function in recent onset insulin-dependent diabetes (the IMDIAB IV study)", Eur. J. Endocrinology, 137, 234-239 (1997)		

BEST AVAILABLE COPY

		1
Examiner's signar re		Date considered
1/1/11/11/	100,100	
<i> </i>		11 611112
1001/001	- Ilon MC V	
1 777 1 3 773 1 7 7	······································	

+ EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. Include copy of this form in next communication to applicant.

• If an assenisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120, 37 C.F.R. 1.98(d).